论文部分内容阅读
目的研究重组人血管内皮抑制素(恩度)联合GP或TP方案化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法选择62例晚期NSCLC患者,分为2组,实验组30例,予GP或TP方案化疗+恩度治疗,恩度7.5 mg/m2第1~14天连续给药,间隔7 d后重复;对照组32例,予单纯GP或TP方案治疗。所有患者至少完成2周期治疗,评判疗效及生活质量(QOL),治疗1周期后评价药物毒副反应。结果实验组有效率(43.3%)与对照组(37.5%)比较,无统计学差异;实验组疾病控制率(86.7%)明显高于对照组(62.5%);试验组中位总生存期(OS)(15个月)、中位无进展生存期(PFS)(10个月)明显长于对照组(10个月、5个月);咳嗽、疲劳积分显示实验组有缓解优势;实验组功能积分改善有优于对照组趋势,但无统计学差异;2组患者不良反应无明显差异。结论恩度联合GP或TP方案化疗治疗晚期NSCLC可提高疾病控制率、中位OS及PFS,且安全性好。
Objective To investigate the efficacy of recombinant human endostatin (Endostar) combined with GP or TP regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Sixty - two patients with advanced NSCLC were divided into two groups. The experimental group was treated with GP or TP regimen plus Endostar. Endostar 7.5 mg / m2 was administered on the 1st to 14th day, Control group of 32 cases, to a simple GP or TP regimen. All patients completed at least 2 cycles of treatment, evaluation of efficacy and quality of life (QOL), treatment of 1 cycle evaluation of drug toxicity. Results The effective rate (43.3%) in the experimental group was not significantly different from that in the control group (37.5%). The disease control rate (86.7%) in the experimental group was significantly higher than that in the control group (62.5% OS) (15 months), median progression-free survival (PFS) (10 months) was significantly longer than that of the control group (10 months and 5 months); cough and fatigue scores showed that the experimental group had mitigation; Integral improvement is better than the control group trend, but no statistical difference; two groups of patients with no significant difference in adverse reactions. Conclusion Endood combined with GP or TP regimen chemotherapy for advanced NSCLC can improve the disease control rate, median OS and PFS, and good safety.